Enliven Therapeutics, Inc. logo

Enliven Therapeutics, Inc.

NASDAQ:ELVN

Overview | Financials
Company Name Enliven Therapeutics, Inc.
Symbol ELVN
Currency USD
Price 17.82
Market Cap 874,356,120
Dividend Yield 0%
52-week-range 13.3 - 30.03
Industry Biotechnology
Sector Healthcare
CEO Mr. Samuel S. Kintz M.B.A.
Website https://www.enliventherapeutics.com

An error occurred while fetching data.

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a

Related Stocks

Financials

Numbers are in millions USD

Numbers are in millions USD